UNLABELLED: Liver regeneration is of major clinical importance in the setting of liver injury, resection, and transplantation. A20, a potent antiinflammatory and nuclear factor kappa B (NF-κB) inhibitory protein, has established pro-proliferative properties in hepatocytes, in part through decreasing expression of the cyclin dependent kinase inhibitor, p21. Both C-terminal (7-zinc fingers; 7Zn) and N-terminal (Nter) domains of A20 were required to decrease p21 and inhibit NF-κB. However, both independently increased hepatocyte proliferation, suggesting that additional mechanisms contributed to the pro-proliferative function of A20 in hepatocytes. We ascribed one of A20's pro-proliferative mechanisms to increased and sustained interleukin (IL)-6-induced signal transducer and activator of transcription 3 (STAT3) phosphorylation, as a result of decreased hepatocyte expression of the negative regulator of IL-6 signaling, suppressor of cytokine signaling 3 (SOCS3). This novel A20 function segregates with its 7Zn not Nter domain. Conversely, total and partial loss of A20 in hepatocytes increased SOCS3 expression, hampering IL-6-induced STAT3 phosphorylation. Following liver resection in mice pro-proliferative targets downstream of IL-6/STAT3 signaling were increased by A20 overexpression and decreased by A20 knockdown. In contrast, IL-6/STAT3 proinflammatory targets were increased in A20-deficient livers, and decreased or unchanged in A20 overexpressing livers. Upstream of SOCS3, levels of its microRNA regulator miR203 were significantly decreased in A20-deficient livers. CONCLUSION: A20 enhances IL-6/STAT3 pro-proliferative signals in hepatocytes by down-regulating SOCS3, likely through a miR203-dependent manner. This finding together with A20 reducing the levels of the potent cell cycle brake p21 establishes its pro-proliferative properties in hepatocytes and prompts the pursuit of A20-based therapies to promote liver regeneration and repair.
UNLABELLED: Liver regeneration is of major clinical importance in the setting of liver injury, resection, and transplantation. A20, a potent antiinflammatory and nuclear factor kappa B (NF-κB) inhibitory protein, has established pro-proliferative properties in hepatocytes, in part through decreasing expression of the cyclin dependent kinase inhibitor, p21. Both C-terminal (7-zinc fingers; 7Zn) and N-terminal (Nter) domains of A20 were required to decrease p21 and inhibit NF-κB. However, both independently increased hepatocyte proliferation, suggesting that additional mechanisms contributed to the pro-proliferative function of A20 in hepatocytes. We ascribed one of A20's pro-proliferative mechanisms to increased and sustained interleukin (IL)-6-induced signal transducer and activator of transcription 3 (STAT3) phosphorylation, as a result of decreased hepatocyte expression of the negative regulator of IL-6 signaling, suppressor of cytokine signaling 3 (SOCS3). This novel A20 function segregates with its 7Zn not Nter domain. Conversely, total and partial loss of A20 in hepatocytes increased SOCS3 expression, hampering IL-6-induced STAT3 phosphorylation. Following liver resection in mice pro-proliferative targets downstream of IL-6/STAT3 signaling were increased by A20 overexpression and decreased by A20 knockdown. In contrast, IL-6/STAT3 proinflammatory targets were increased in A20-deficient livers, and decreased or unchanged in A20 overexpressing livers. Upstream of SOCS3, levels of its microRNA regulator miR203 were significantly decreased in A20-deficient livers. CONCLUSION:A20 enhances IL-6/STAT3 pro-proliferative signals in hepatocytes by down-regulating SOCS3, likely through a miR203-dependent manner. This finding together with A20 reducing the levels of the potent cell cycle brake p21 establishes its pro-proliferative properties in hepatocytes and prompts the pursuit of A20-based therapies to promote liver regeneration and repair.
Authors: Maria B Arvelo; Jeffrey T Cooper; Christopher Longo; Soizic Daniel; Shane T Grey; Jerome Mahiou; Eva Czismadia; Graziella Abu-Jawdeh; Christiane Ferran Journal: Hepatology Date: 2002-03 Impact factor: 17.425
Authors: Ingrid E Wertz; Karen M O'Rourke; Honglin Zhou; Michael Eby; L Aravind; Somasekar Seshagiri; Ping Wu; Christian Wiesmann; Rohan Baker; David L Boone; Averil Ma; Eugene V Koonin; Vishva M Dixit Journal: Nature Date: 2004-07-18 Impact factor: 49.962
Authors: Soizic Daniel; Maria B Arvelo; Virendra I Patel; Christopher R Longo; Gautam Shrikhande; Tala Shukri; Jerome Mahiou; David W Sun; Christina Mottley; Shane T Grey; Christiane Ferran Journal: Blood Date: 2004-07-13 Impact factor: 22.113
Authors: Alex Blindenbacher; Xueya Wang; Igor Langer; Rocco Savino; Luigi Terracciano; Markus H Heim Journal: Hepatology Date: 2003-09 Impact factor: 17.425
Authors: Ben A Croker; Danielle L Krebs; Jian-Guo Zhang; Sam Wormald; Tracy A Willson; Edouard G Stanley; Lorraine Robb; Christopher J Greenhalgh; Irmgard Förster; Björn E Clausen; Nicos A Nicola; Donald Metcalf; Douglas J Hilton; Andrew W Roberts; Warren S Alexander Journal: Nat Immunol Date: 2003-05-18 Impact factor: 25.606
Authors: Scott M Damrauer; Peter Studer; Cleide G da Silva; Christopher R Longo; Haley E Ramsey; Eva Csizmadia; Gautam V Shrikhande; Salvatore T Scali; Towia A Libermann; Manoj K Bhasin; Christiane Ferran Journal: PLoS One Date: 2011-03-17 Impact factor: 3.240
Authors: P Studer; C G da Silva; J M Revuelta Cervantes; A Mele; E Csizmadia; J J Siracuse; S M Damrauer; C R Peterson; D Candinas; D M Stroka; A Ma; M Bhasin; C Ferran Journal: Cell Death Differ Date: 2015-05-15 Impact factor: 15.828
Authors: J A Reihill; B Malcomson; A Bertelsen; S Cheung; A Czerwiec; R Barsden; J S Elborn; H Dürkop; B Hirsch; M Ennis; C Kelly; B C Schock Journal: Br J Pharmacol Date: 2015-07-21 Impact factor: 8.739
Authors: Annie Rocio Piñeros Alvarez; Nicole Glosson-Byers; Stephanie Brandt; Soujuan Wang; Hector Wong; Sarah Sturgeon; Brian Paul McCarthy; Paul R Territo; Jose Carlos Alves-Filho; C Henrique Serezani Journal: JCI Insight Date: 2017-07-06